Compare · BFLY vs NDRA
BFLY vs NDRA
Side-by-side comparison of Butterfly Network Inc. (BFLY) and ENDRA Life Sciences Inc. (NDRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BFLY focuses on Medical Electronics, while NDRA focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- BFLY is the larger of the two at $1.54B, about 261.3x NDRA ($5.9M).
- BFLY has been more active in the news (14 items in the past 4 weeks vs 3 for NDRA).
- BFLY has more recent analyst coverage (11 ratings vs 0 for NDRA).
- Company
- Butterfly Network Inc.
- ENDRA Life Sciences Inc.
- Price
- -
- -
- Market cap
- $1.54B
- $5.9M
- 1M return
- -23.13%
- -
- 1Y return
- +185.36%
- -
- Industry
- Medical Electronics
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- 2017
- News (4w)
- 14
- 3
- Recent ratings
- 11
- 0
Butterfly Network Inc.
Butterfly Network, Inc., a digital health company, develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; and Butterfly iQ+, a point-of-care ultrasound imaging device that connects with a smart phone or tablet. The company serves healthcare practitioners. Butterfly Network, Inc. was incorporated in 2011 and is headquartered in Guilford, Connecticut.
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Latest BFLY
- Director Jonathan M Rothberg sold $2,227,629 worth of Class B Common Stock (359,382 units at $6.20) as part of a pre-agreed trading plan (SEC Form 4)
- Butterfly Network to Present at 9th Annual Evercore Healthcare Conference on December 1, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Butterfly Network Inc.
- SEC Form 144 filed by Butterfly Network Inc.
- EVP, CFO Doherty John N. sold $350,000 worth of shares (50,000 units at $7.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,347,276 units (SEC Form 4)
- SEC Form 144 filed by Butterfly Network Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Butterfly Network Inc.
- President & CEO Devivo Joseph sold $634,925 worth of shares (90,600 units at $7.01), decreasing direct ownership by 1% to 7,221,330 units (SEC Form 4)
- SEC Form 144 filed by Butterfly Network Inc.
- SEC Form S-3ASR filed by Butterfly Network Inc.
Latest NDRA
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
- SEC Form SCHEDULE 13G filed by ENDRA Life Sciences Inc.
- SEC Form 425 filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 425 filed by ENDRA Life Sciences Inc.
- SEC Form 425 filed by ENDRA Life Sciences Inc.
- SEC Form 425 filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ASP Isotopes Issues Letter to Shareholders